251 related articles for article (PubMed ID: 30398003)
1. Anti-TIF1γ antibody and the expression of TIF1γ in idiopathic inflammatory myopathies.
Kim Y; Song KS; Sohn EH; Kang SW; Yoo IS; Shim SC; Yoo SJ; Kim J
Int J Rheum Dis; 2019 Feb; 22(2):314-320. PubMed ID: 30398003
[TBL] [Abstract][Full Text] [Related]
2. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
3. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies.
Wong VT; So H; Lam TT; Yip RM
Acta Neurol Scand; 2021 Feb; 143(2):131-139. PubMed ID: 32762037
[TBL] [Abstract][Full Text] [Related]
4. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis.
Kotobuki Y; Tonomura K; Fujimoto M
Immunol Med; 2021 Mar; 44(1):23-29. PubMed ID: 32649853
[TBL] [Abstract][Full Text] [Related]
6. Anti-TIF1γ antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays.
Labrador-Horrillo M; Martínez MA; Selva-O'Callaghan A; Trallero-Araguás E; Balada E; Vilardell-Tarrés M; Juarez C
Ann Rheum Dis; 2012 Jun; 71(6):993-6. PubMed ID: 22294626
[TBL] [Abstract][Full Text] [Related]
7. Anti-TIF1-γ antibody and cancer-associated myositis: A clinicohistopathologic study.
Hida A; Yamashita T; Hosono Y; Inoue M; Kaida K; Kadoya M; Miwa Y; Yajima N; Maezawa R; Arai S; Kurasawa K; Ito K; Shimada H; Iwanami T; Sonoo M; Hatanaka Y; Murayama S; Uchibori A; Chiba A; Aizawa H; Momoo T; Nakae Y; Sakurai Y; Shiio Y; Hashida H; Yoshizawa T; Sakiyama Y; Oda A; Inoue K; Takeuchi S; Iwata NK; Date H; Masuda N; Mikata T; Motoyoshi Y; Uesaka Y; Maeda MH; Nakashima R; Tsuji S; Kwak S; Mimori T; Shimizu J
Neurology; 2016 Jul; 87(3):299-308. PubMed ID: 27343066
[TBL] [Abstract][Full Text] [Related]
8. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
Fujimoto M; Murakami A; Kurei S; Okiyama N; Kawakami A; Mishima M; Sato S; Seishima M; Suda T; Mimori T; Takehara K; Kuwana M
J Dermatol Sci; 2016 Dec; 84(3):272-281. PubMed ID: 27693019
[TBL] [Abstract][Full Text] [Related]
9. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
[TBL] [Abstract][Full Text] [Related]
10. Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis.
Okiyama N; Ichimura Y; Shobo M; Tanaka R; Kubota N; Saito A; Ishitsuka Y; Watanabe R; Fujisawa Y; Nakamura Y; Murakami A; Kayama H; Takeda K; Fujimoto M
Ann Rheum Dis; 2021 Sep; 80(9):1201-1208. PubMed ID: 33811031
[TBL] [Abstract][Full Text] [Related]
11. Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis.
Pinal-Fernandez I; Ferrer-Fabregas B; Trallero-Araguas E; Balada E; Martínez MA; Milisenda JC; Aparicio-Español G; Labrador-Horrillo M; Garcia-Patos V; Grau-Junyent JM; Selva-O'Callaghan A
Rheumatology (Oxford); 2018 Feb; 57(2):388-396. PubMed ID: 29149307
[TBL] [Abstract][Full Text] [Related]
12. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study.
Yang H; Peng Q; Yin L; Li S; Shi J; Zhang Y; Lu X; Shu X; Zhang S; Wang G
Arthritis Res Ther; 2017 Nov; 19(1):259. PubMed ID: 29178913
[TBL] [Abstract][Full Text] [Related]
13. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
14. A Commercial Anti-TIF1γ ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing.
Mulhearn B; Li D; McMorrow F; Lu H; McHugh NJ; Tansley SL
Front Immunol; 2022; 13():804037. PubMed ID: 35154119
[TBL] [Abstract][Full Text] [Related]
15. Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation.
Aggarwal R; Oddis CV; Goudeau D; Fertig N; Metes I; Stephens C; Qi Z; Koontz D; Levesque MC
Rheumatology (Oxford); 2014 Mar; 53(3):433-7. PubMed ID: 24255164
[TBL] [Abstract][Full Text] [Related]
16. The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.
Aussy A; Fréret M; Gallay L; Bessis D; Vincent T; Jullien D; Drouot L; Jouen F; Joly P; Marie I; Meyer A; Sibilia J; Bader-Meunier B; Hachulla E; Hamidou M; Huë S; Charuel JL; Fabien N; Viailly PJ; Allenbach Y; Benveniste O; Cordel N; Boyer O;
Arthritis Rheumatol; 2019 Aug; 71(8):1360-1370. PubMed ID: 30896088
[TBL] [Abstract][Full Text] [Related]
17. A Case of Dermatomyositis Along with Esophageal Cancer and Screening of Serum Transcriptional Intermediary Factor 1 Gamma Antibodies in Various Cancer Patients.
Sumazaki M; Kaneko K; Ito M; Oshima Y; Saito F; Ogata H; Shibuya K; Shimada H
Am J Case Rep; 2020 Apr; 21():e922004. PubMed ID: 32312948
[TBL] [Abstract][Full Text] [Related]
18. A New Immunodot Assay for Multiplex Detection of Autoantibodies in a Cohort of Italian Patients With Idiopathic Inflammatory Myopathies.
Tampoia M; Notarnicola A; Abbracciavento L; Fontana A; Giannini M; Louis Humbel R; Iannone F
J Clin Lab Anal; 2016 Nov; 30(6):859-866. PubMed ID: 27074881
[TBL] [Abstract][Full Text] [Related]
19. Murine models of idiopathic inflammatory myopathies.
Okiyama N; Konishi R; Ichimura Y
J Dermatol; 2024 Feb; ():. PubMed ID: 38321631
[TBL] [Abstract][Full Text] [Related]
20. Age distribution and prevalence in different age groups of four myositis-specific autoantibodies, including anti-ARS, anti-MDA5, anti-Mi-2, and anti-TIF1γ antibodies.
Ueda-Hayakawa I; Tonomura K; Maekawa A; Kaneda E; Arase N; Fujimoto M
J Dermatol; 2023 Aug; 50(8):1058-1062. PubMed ID: 36890683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]